IRIS
PATRIARCA, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.742
AS - Asia 6.007
EU - Europa 3.866
SA - Sud America 1.284
AF - Africa 128
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 6
Totale 25.049
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.527
SG - Singapore 2.809
CN - Cina 1.314
UA - Ucraina 1.067
BR - Brasile 1.037
HK - Hong Kong 631
DE - Germania 573
VN - Vietnam 481
IT - Italia 477
FI - Finlandia 410
RU - Federazione Russa 304
FR - Francia 250
SE - Svezia 242
IE - Irlanda 207
IN - India 138
CA - Canada 128
GB - Regno Unito 121
TR - Turchia 112
BD - Bangladesh 108
AR - Argentina 90
KR - Corea 74
IQ - Iraq 63
MX - Messico 43
CO - Colombia 41
EC - Ecuador 38
NL - Olanda 37
AT - Austria 31
ZA - Sudafrica 30
JP - Giappone 29
PL - Polonia 29
ID - Indonesia 28
PK - Pakistan 27
IR - Iran 21
BE - Belgio 20
UZ - Uzbekistan 20
MA - Marocco 19
VE - Venezuela 19
CL - Cile 18
PH - Filippine 17
PY - Paraguay 17
SA - Arabia Saudita 17
CZ - Repubblica Ceca 14
EU - Europa 14
TN - Tunisia 14
KE - Kenya 13
AE - Emirati Arabi Uniti 12
ES - Italia 12
MY - Malesia 12
PE - Perù 12
RO - Romania 12
AZ - Azerbaigian 9
EG - Egitto 9
NP - Nepal 9
RS - Serbia 9
CH - Svizzera 8
JM - Giamaica 8
JO - Giordania 8
KZ - Kazakistan 8
TG - Togo 8
OM - Oman 7
PA - Panama 7
AU - Australia 6
DZ - Algeria 6
GE - Georgia 6
IL - Israele 6
KG - Kirghizistan 6
AL - Albania 5
BO - Bolivia 5
GA - Gabon 5
HN - Honduras 5
LT - Lituania 5
UY - Uruguay 5
BG - Bulgaria 4
BH - Bahrain 4
GT - Guatemala 4
LB - Libano 4
NI - Nicaragua 4
PS - Palestinian Territory 4
PT - Portogallo 4
TH - Thailandia 4
TW - Taiwan 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
BY - Bielorussia 3
CM - Camerun 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
LV - Lettonia 3
MD - Moldavia 3
SN - Senegal 3
AM - Armenia 2
AO - Angola 2
CR - Costa Rica 2
DK - Danimarca 2
GY - Guiana 2
KH - Cambogia 2
MN - Mongolia 2
NG - Nigeria 2
QA - Qatar 2
SI - Slovenia 2
Totale 25.012
Salva come PNG Salva come JPEG
Città #
Fairfield 1.589
Woodbridge 1.361
Singapore 1.129
Ashburn 1.110
Houston 1.005
Ann Arbor 893
Jacksonville 701
Wilmington 644
Seattle 637
Hong Kong 627
Beijing 609
Chandler 569
Cambridge 509
Dearborn 454
San Jose 430
Boardman 270
Dallas 228
Lauterbourg 216
Princeton 211
Dublin 204
Los Angeles 158
Ho Chi Minh City 153
Udine 150
Council Bluffs 107
San Diego 100
Buffalo 96
São Paulo 96
Hanoi 94
Hefei 89
Redondo Beach 79
Izmir 78
New York 72
Dong Ket 69
Seoul 68
Munich 66
Helsinki 57
Ogden 52
Santa Clara 50
Des Moines 46
Norwalk 43
Nuremberg 41
Ottawa 41
Frankfurt am Main 39
The Dalles 38
Rio de Janeiro 33
Montreal 31
Kunming 28
Trieste 28
Pittsburgh 27
Turku 27
Nanjing 26
Baghdad 25
Toronto 25
Chicago 24
Mumbai 24
Warsaw 24
Dhaka 22
Rome 22
Tokyo 22
Atlanta 21
Belo Horizonte 21
Curitiba 21
Lappeenranta 21
Denver 20
Brasília 19
Guangzhou 19
Haiphong 19
Redmond 19
Bogotá 18
Brussels 18
Da Nang 18
Chennai 17
Shanghai 17
Tashkent 17
Orem 16
Poplar 16
Stockholm 16
Hyderabad 15
Nanchang 15
Salvador 15
Brooklyn 14
Phoenix 14
Amsterdam 13
Guayaquil 13
Porto Alegre 13
Shenzhen 13
Simi Valley 13
Boston 12
Campinas 12
Düsseldorf 12
London 12
Quito 12
Vienna 12
Ankara 11
Duino-Aurisina 11
Fortaleza 11
Johannesburg 11
Manchester 11
Milan 11
Shenyang 11
Totale 16.286
Salva come PNG Salva come JPEG
Nome #
Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy 278
Combined orthotopic heart transplantation followed by autologous stem cell transplantation in a patient with light chain amyloidosis and isolated cardiac involvement 223
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 213
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 211
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 200
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)” 197
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. 189
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 186
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 184
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). 180
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 179
The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation 179
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: A multicenter retrospective study based on donor availability 179
A comparison of allografting with autografting for newly diagnosed myeloma 175
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 168
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 168
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 166
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 166
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. 165
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 162
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 160
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 160
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 159
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 157
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 156
JAK-2 inhibitors and allogeneic transplant in myelofibrosis 155
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation 154
Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation 154
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group 154
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 151
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 151
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 149
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. 149
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease 148
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. 147
Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon. 147
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 145
Acute myeloid leukemia following chronic low-dose cyclophosphamide in metastatic breast cancer 143
Rituximab for the treatment of type II mixed cryoglobulinemia 143
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 143
Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma 143
‘Real-life’ report on the management of chronic GvHD in the gruppo Italiano trapianto midollo osseo (GITMO) 142
Defibrotide : review on clinical use and future development 140
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 140
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 139
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 139
Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. 138
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 137
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. 136
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. 135
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 134
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 134
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 134
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 133
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. 132
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide 132
Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant patients: intercontinental prospective study of Infectious Diseases Working Party of the European Bone Marrow Transplantation group 132
Flow cytometry evaluation of plasma cells contaminating leukapheresis pre- and post- CD34-positive selection- 130
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey in 50 patients 130
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 129
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 129
Multiple Myeloma: presenting features and survival according to hospital referral 128
Albumina: ricaduta delle linee guida aziendali sui consumi 128
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 127
A prospective comparison of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disaese in newly diagnosed multiple myeloma 127
Qualitative and quantitative polymerase chain reaction monitoring minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation . 127
Sequential study of cytokine and lymphocyte patterns in patients with chronic agraft versus host disease after reduced intensity conditioning allogenic stem cell transplantation 126
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 126
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. 125
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 125
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 124
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 124
High dose therapy with stem cell rescue in elderly atients with aggressive poor risk lymphomas: a review of 14 cases. 123
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients 123
Long lasting remission after haploidentical stem cell transplant and pre-emptive donor lymphocyte infusions in a patient with primary refractory Hodgkin lymphoma 122
Impact of Cryopreservation of Peripheral Blood Stem Cells (PBSC) in Transplantation from Matched Unrelated Donor (MUD) 121
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. 121
Experts' considerations on HLA-haploidentical stem cell transplantation. 119
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. 119
Cytokines dysregulation and chronic graft versus host disease after allogeneic haematopoieitc stem cell transplantation with reduced intensity conditioning 118
FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 60 YEARS WITH POOR RISK ACUTE MYELOID LEUKEMIA 118
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. 118
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 118
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group 117
Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy 116
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 116
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous: a retrospective study based on the time of HLA typing and donor availability 116
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 115
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 115
Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo 115
Aspirin, warfarin or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label randomized trial 114
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. 114
Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. 114
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation 113
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. 113
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation 113
Autologous transplantation and maintenance therapy in multiple myeloma 113
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 113
Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura 112
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 112
Totale 14.279
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.306
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.306
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021470 0 0 0 0 0 0 0 0 0 0 288 182
2021/20221.611 68 205 85 102 37 69 101 77 15 269 328 255
2022/20231.465 224 73 13 177 142 428 1 103 220 17 32 35
2023/2024489 64 28 10 17 67 53 25 43 81 46 26 29
2024/20253.788 86 285 121 89 295 190 184 240 351 368 551 1.028
2025/20267.114 547 783 681 791 988 621 886 275 488 735 319 0
Totale 25.723